{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:35:37Z","timestamp":1789598137187,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2022,7,20]]},"abstract":"<jats:p>Fosfomycin is a phosphonic acid derivative active against a wide spectrum of Gram-positive and Gram-negative pathogens. It is used for the treatment of uncomplicated urinary tract infections (uUTI) or severe infections by oral or intravenous (i.v.) administration.<\/jats:p>","DOI":"10.1128\/jcm.00021-22","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T13:00:57Z","timestamp":1655989257000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["Multicenter Evaluation of the Novel ETEST Fosfomycin for Antimicrobial Susceptibility Testing of Enterobacterales, Enterococcus faecalis, and Staphylococcus Species"],"prefix":"10.1128","volume":"60","author":[{"given":"A.","family":"Goer","sequence":"first","affiliation":[{"name":"Institut fuer Medizinische Laboratiums Diagnostik &amp; National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Department of Medical Microbiology, Ruhr-University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5087-7500","authenticated-orcid":true,"given":"L. S.","family":"Blanchard","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux Global Clinical Affairs, Marcy-L\u2019\u00c9toile, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Van Belkum","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, La Balme les Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J.","family":"Loftus","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux Global Clinical Affairs, Hazelwood, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. P.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux Global Clinical Affairs, Hazelwood, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G.","family":"Gatermann","sequence":"additional","affiliation":[{"name":"Institut fuer Medizinische Laboratiums Diagnostik &amp; National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Department of Medical Microbiology, Ruhr-University, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5216","authenticated-orcid":true,"given":"D.","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Olson","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Health System, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. K.","family":"Meece","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Health System, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. R.","family":"Fritsche","sequence":"additional","affiliation":[{"name":"Marshfield Clinic Health System, Marshfield, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pompilio","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, La Balme les Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Halimi","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, La Balme les Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Franceschi","sequence":"additional","affiliation":[{"name":"bioM\u00e9rieux, La Balme les Grottes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.122"},{"key":"e_1_3_2_3_2","unstructured":"FDA. 2011. Monurol. Reference ID: 2930481."},{"key":"e_1_3_2_4_2","unstructured":"European Medicines Agency. 2021. Fosfomycin_public health communication_Post EC decision. https:\/\/www.ema.europa.eu\/en."},{"key":"e_1_3_2_5_2","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. http:\/\/www.eucast.org."},{"key":"e_1_3_2_6_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2020. Fosfomycin: general consultation on fosfomycin oral for Enterobacterales consultation period 2. http:\/\/www.eucast.org."},{"key":"e_1_3_2_7_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2013. Fosfomycin: rationale for the clinical breakpoints version 1.0. http:\/\/www.eucast.org."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080500"},{"key":"e_1_3_2_9_2","first-page":"1","article-title":"New perspectives for reassessing fosfomycin: applicability in current clinical practice","volume":"32","author":"Candel FJ","year":"2019","unstructured":"Candel FJ, Matesanz David M, Barber\u00e1n J. 2019. New perspectives for reassessing fosfomycin: applicability in current clinical practice. Revista Espanola de Quimioterapia 32:1\u20137.","journal-title":"Revista Espanola de Quimioterapia"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2020.01.014"},{"key":"e_1_3_2_11_2","first-page":"8","article-title":"New microbiological aspects of fosfomycin","volume":"32","author":"D\u00edez-Aguilar M","year":"2019","unstructured":"D\u00edez-Aguilar M, Cant\u00f3n R. 2019. New microbiological aspects of fosfomycin. Rev Esp Quimioter 32:8\u201318.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/527442"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.13.5.705"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.06.014"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl545"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky214"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinmicnews.2020.01.004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01635-21"},{"key":"e_1_3_2_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing.","author":"CLSI","year":"2021","unstructured":"CLSI. 2021. Performance standards for antimicrobial susceptibility testing. 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_2_21_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically.","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_22_2","volume-title":"FDA guidance for industry: class II special controls guidance document: antimicrobial susceptibility test (AST) systems.","author":"FDA","year":"2009","unstructured":"FDA. 2009. FDA guidance for industry: class II special controls guidance document: antimicrobial susceptibility test (AST) systems. FDA, Silver Spring, MD."},{"key":"e_1_3_2_23_2","volume-title":"ISO\/FDIS 20776 \u22122:2007(E) clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infection agents and evaluation of performance of antimicrobial susceptibility test devices\u2014part 2, evaluation of performance of antimicrobial susceptibility test devices.","author":"ISO","year":"2007","unstructured":"ISO. 2007. ISO\/FDIS 20776 \u22122:2007(E) clinical laboratory testing and in vitro diagnostic test systems. Susceptibility testing of infection agents and evaluation of performance of antimicrobial susceptibility test devices\u2014part 2, evaluation of performance of antimicrobial susceptibility test devices. ISO, Geneva, Switzerland."},{"key":"e_1_3_2_24_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2013. Fosfomycin trometamol: rationale for the clinical breakpoints version 1.0. http:\/\/www.eucast.org."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00634-19"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03484-13"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00021-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00021-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T13:02:00Z","timestamp":1658322120000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00021-22"}},"subtitle":[],"editor":[{"given":"Patricia J.","family":"Simner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7,20]]}},"alternative-id":["10.1128\/jcm.00021-22"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00021-22","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"2022-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00021-22"}}